1. Home
  2. LOAN vs CELU Comparison

LOAN vs CELU Comparison

Compare LOAN & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Manhattan Bridge Capital Inc

LOAN

Manhattan Bridge Capital Inc

HOLD

Current Price

$4.79

Market Cap

51.9M

Sector

Real Estate

ML Signal

HOLD

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$1.83

Market Cap

56.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOAN
CELU
Founded
1989
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.9M
56.7M
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
LOAN
CELU
Price
$4.79
$1.83
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
41.3K
62.1K
Earning Date
10-24-2025
11-14-2025
Dividend Yield
9.54%
N/A
EPS Growth
N/A
N/A
EPS
0.46
N/A
Revenue
$7,138,128.00
$40,578,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.47
$76.00
P/E Ratio
$10.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.29
$1.00
52 Week High
$6.05
$4.35

Technical Indicators

Market Signals
Indicator
LOAN
CELU
Relative Strength Index (RSI) 55.85 44.20
Support Level $4.64 $1.62
Resistance Level $4.83 $2.01
Average True Range (ATR) 0.14 0.12
MACD 0.05 0.01
Stochastic Oscillator 96.67 23.81

Price Performance

Historical Comparison
LOAN
CELU

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: